CEFONICID

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H18N6O8S3
Molecular Weight	542.566
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C4=CC=CC=C4)C(O)=O

InChI

InChIKey=DYAIAHUQIPBDIP-AXAPSJFSSA-N

InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H18N6O8S3
Molecular Weight	542.566
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Cefonicid is a semi-synthetic broad-spectrum cephalosporin antibiotic resistant to beta-lactamases. Similarly to other cephalosporins, cefonicid exerts its antibacterial activity through the inhibition of the bacterial cell-wall synthesis. Its in vitro and in vivo activity against a wide range of Gram-positive and Gram-negative microorganisms is documented.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 233	Inhibitor 8,297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bacterial infections 234	Curative		Approved 8,429	MONOCID

C_max

Value	Dose	Co-administered	Analyte	Population
127 μg/mL	1 g single, intramuscular		CEFONICID serum	Homo sapiens
213 μg/mL	50 mg/kg bw single, intramuscular		CEFONICID serum	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
1644 μg × h/mL	1 g single, intramuscular		CEFONICID serum	Homo sapiens
1.11 μg × h/mL	50 mg/kg bw single, intramuscular		CEFONICID serum	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.6 h	1 g single, intramuscular		CEFONICID serum	Homo sapiens
3.24 h	50 mg/kg bw single, intramuscular		CEFONICID serum	Homo sapiens

Doses

Doses

Show entries

Dose	Population	Adverse events
1 g single, intramuscular	unhealthy, 19 - 88 years n = 57
1 g single, intravenous	unhealthy, 19 - 88 years n = 57
50 mg/kg single, intramuscular	unhealthy, 36 -142 months n = 17
2 g 2 times / day single, intravenous Highest studied dose	unhealthy, 59.9 ± 10.74 years n = 30

Showing 1 to 4 of 4 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3491	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3491
ChemicalBook	CB5283109	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5283109
ZINC	ZINC000003830428	http://zinc15.docking.org/substances/ZINC000003830428

Showing 1 to 3 of 3 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Impact of drug policy on the use of parenteral cephalosporins in Italy.	2002 Oct	12426958
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942

Showing 1 to 3 of 3 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage is 1 g CEFONICID administered once every 24 hours, intravenously or by deep intramuscular injection. Daily doses higher than 1 g are rarely necessary. However, in exceptional cases, doses up to 2 g given once daily have been well tolerated. In case of administration of 2 g I.M. once daily, half the dose should be administered in different large muscle masses.

Route of Administration: Other

In Vitro Use Guide

The MIC50 and MIC90 for the 60 strains of viridans group streptococci isolated from blood of patients with bacteremia and infective endocarditis were 4 and 32 micrograms/ml for cefonicid.